1140 results for 'Akt'

Protein kinase B or AKT (PKB) is a serine/threonine kinase. In mammals it is comprised of 3 highly homologous isoforms PKBα (Akt1), PKBβ (Akt2), and PKBγ (Akt3) (Manning and Cantley 2007). AKT

PI3K does not switch on a protein — it rewrites a membrane. Everything downstream follows from one chemical event: the 3-hydroxyl of a phosphoinositide is phosphorylated, PIP₂ becomes PIP₃, and every

Quick Facts About PonsegromabWhat is Ponsegromab?Ponsegromab is an investigational monoclonal antibody developed by Pfizer, primarily studied for its potential in treating heart failure

Quick Facts About Tisotumab VedotinWhat is Tisotumab Vedotin?Tisotumab Vedotin (Tivdak™) is an antibody-drug conjugate (ADC) designed to target tissue factor (TF) and is FDA-approved for

The prevalence of obesity and its associated metabolic disorders has risen dramatically in recent decades, presenting a significant global health challenge. Adipose tissue, once considered mere

Signal 1 tells a T cell what it is looking at; signal 2 tells it whether to care. The same peptide–MHC engagement that launches a productive effector response can just as easily install an anergy pro

Breakthrough Discovery: Epstein-Barr Virus Identified as Primary Trigger for Lupus A groundbreaking study published in November 2025 has provided the most definitive evidence to date that the common E

Quick Facts About UlviprubartWhat is Ulviprubart?Ulviprubart is an experimental complement inhibitor designed to modulate immune responses in autoimmune diseases.What is the mechanism of

Kreuzreaktivität ELISA: Praxisleitfaden für Forschende Kreuzreaktivität im ELISA bedeutet, dass ein Antikörper an ein strukturell ähnliches Nicht-Ziel bindet und dadurch falsch-positive oder verfälsc

Almost all of the TGF-β in a tissue is already there, and almost none of it is active. That single fact reorganises how the pathway should be studied. Unlike most cytokines, TGF-β is deposited into t

Quick Facts About MonalizumabWhat is Monalizumab?Monalizumab is a first-in-class immune checkpoint inhibitor targeting NKG2A, developed to enhance anti-tumor immune response by blocking

A New Dawn in Cancer Treatment: Reprogramming the Immune System's Own Soldiers For decades, the fight against cancer has been a relentless battle of attrition, with treatments like chemotherapy and r

Quick Facts About BrodalumabWhat is Brodalumab?Brodalumab is a monoclonal antibody that targets the IL-17 receptor to treat immune-mediated conditions like moderate-to-severe plaque psor

Quick Facts About TezepelumabWhat is Tezepelumab?Tezepelumab is a monoclonal antibody designed to inhibit thymic stromal lymphopoietin (TSLP), a key driver of airway inflammation in seve

Quick Facts About VolagidemabWhat is Volagidemab?Volagidemab is a glucagon-like peptide-1 (GLP-1) receptor antagonist designed to regulate glucose metabolism and energy homeostasis.How D

Quick Facts About ZolbetuximabWhat is Zolbetuximab?Zolbetuximab is a monoclonal antibody that targets Claudin 18.2, a protein overexpressed in gastric and pancreatic cancers, enhancing t